Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Open Orphan Plc ( (GB:HVO) ) has issued an update.
hVIVO plc has acquired two Clinical Research Units (CRUs) from CRS Clinical Research Services Management GmbH in Germany for €10 million, funded from existing cash resources. This acquisition marks hVIVO’s initial step in its M&A strategy, enhancing its service portfolio with Phase I and in-patient Phase II trials, and establishing a significant European presence with 120 beds. The acquisition is expected to be earnings accretive by 2026, and aims to drive growth through cross-selling opportunities with Venn Life Sciences, broadening the client base and revenue streams. With a pro forma weighted contracted orderbook of £67 million for 2025, hVIVO anticipates strong revenue growth and improved EBITDA margins post-integration, solidifying its position in the clinical research industry.
More about Open Orphan Plc
hVIVO plc is a fast-growing early-stage Contract Research Organisation (CRO) and a world leader in human challenge clinical trials. The company focuses on early-phase clinical development services, including first-in-human and proof-of-concept trials, and is expanding its service offerings to include Phase I and Phase II trials across various therapeutic areas.
YTD Price Performance: 2.93%
Average Trading Volume: 3,019,832
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £133.4M
Find detailed analytics on HVO stock on TipRanks’ Stock Analysis page.
